The discovery of an overpayment raises serious questions about compliance requirements. Understand your organization’s reporting obligation and appropriate methods for determining overpayments.
The full U.S Court of Appeals declined to reconsider two recent decisions that upheld CMS’ cuts to reimbursement for certain off-campus provider-based department (PBD) visits and drugs acquired under the 340B program, the American Hospital Association (AHA) announced October 19.
This week’s Medicare updates include the latest edition of the Medicare Quarterly Provider Compliance Newsletter, two new proposed decision memos on coverage for blood-based biomarker tests and a molecular expression test, updated information in the COVID-19 billing FAQs, and more!
Q: Can an independent radiology facility mail postcards with a reminder that it's time for patients to schedule? The postcard would include the patient's name and address, obviously, but then either a check mark by screening mammogram or the words “follow-up exam.”
Q: Starting January 1, 2021, CMS will be lowering reimbursement for high throughput novel coronavirus (COVID-19) diagnostic tests from $100 to $75. I understand that if certain requirements are met labs will be eligible to bill for a $25 add on code. How can we meet the requirements for the add on code?
